23andMe IPO

23andme.comHealthcareFounded: 2006Funding to Date: $791.61MM

23andMe, founded in April 2006 by Linda Avey, Paul Cusenza, and Anne Wojcicki. The company has not officially endorsed a plan to participate in an IPO.

23andMe provides at-home, consumer genetic testing and was the first FDA-approved direct-to-consumer genetic sequencing supplier. More recently, 23andMe has leveraged its genetic database in pursuit of pharmaceutical drug development. The company has raised nearly $800 million in Venture Capital funding from investors including GlaxoSmithKline, Pegasus Tech Ventures, MicroVentures, G Squared, Sapphire Ventures, Sequoia Capital, SharesPost, Fidelity, GV, and Genetech. It has been widely reported that 23andMe last raised $300 million in July 2018 at a post-money valuation of $2.5 billion.

Register for Details

For more details on financing and valuation for 23andMe, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Valuation

Date of Last Funding Round

July 2018

Amount Last Raised

$2.51 B

Value at Last Round

$300 MM

Total Funding to Date

$791.61 MM

Enterprise Value (based on primary financings)